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Divergent, stereoselective access to heterocyclic
α,α-quaternary- and β2,3,3-amino acid derivatives
from a N-Pmp-protected Orn-derived β-lactam†‡
Diego Núñez-Villanueva, M. Teresa García-López, Mercedes Martín-Martínez and
Rosario González-Muñiz*
A suitably protected Orn-derived (3S,4S)-β-lactam was used as common intermediate in the synthesis of
conformationally constrained (3S,4S)-2-oxoazepane α,α- and (2S,3S)-2-oxopiperidine-β2,3,3-amino acid
derivatives. Compared to alternative procedures using an N-p-methoxybenzyl group at the 2-azetidinone,
the incorporation of a p-methoxyphenyl moiety is crucial for the excellent stereochemical outcomes
in the preparation of these heterocyclic amino acids. Chemoselective 7- or 6-exo-trig cyclization was
achieved through alternative sequences of Pmp-deprotection/Boc-activation, followed by inter- and
intramolecular β-lactam ring opening, respectively.
Introduction
In the design of peptidomimetics the incorporation of confor-
mational constraints into bioactive peptides is a fundamental
strategy to obtain information about their active conformation
when interacting with therapeutic targets.1–3 Either global or
local restrictions of the conformational space can be used to
rigidify peptide-like molecules. Among the latter, the insertion
of α,α-disubstituted amino acids has served to stabilize both
β-turn and α-helix-type conformations, depending on the
length of the peptide derivative and on the α-substituents.4
While acyclic and diﬀerent size carbocyclic α,α-quaternary
α-amino acids have been thoroughly studied, only a few
examples of heterocyclic derivatives have been described.5–8
In the case of N-containing heterocycles, the heteroatom could
not only serve to interact with the environment, contributing
to increase the solubility of the final peptide, but also as an
anchoring point for substituents that could mimic important
side-chains.9
Although less studied, β-peptides, oligomers of β-amino
acids, or mixed α,β-peptides can also adopt specific confor-
mations, depending on the backbone carbon substituted
(β2, β3, β2,2, β2,3, β3,3, β2,2,3) and on the relative configuration
of the substituents.10–12 Again, only a few examples of
β2,2- or β3,3-substituted amino acids bearing heterocyclic rings
at 2 or 3 positions have been described in the literature.13–15
Among them, we can highlight some pyrrolidine and piper-
idine derivatives that constitute the central core of selective
inhibitors of tumor necrosis factor-α.13,14
The possibility that subtle changes in the structure of these
α,α- and β-amino acids could result in diﬀerent stabilization of
peptide conformations has prompted a continuous interest in
these restricted non-proteinogenic amino acids.16–23 Within
this context, previous work in our group has led to the prepa-
ration of novel 2-oxoazepane (X = CO) and azepane (X = CH2)
quaternary amino acid derivatives 2 that induce the adoption
of β-turn conformations when incorporated into dipeptide
derivatives.24,25 When amino acids 2 (X = CH2) were integrated
in tripeptides, at any of the possible positions, we observed
the preferential adoption of 310 helical structures, both in solu-
tion and in the solid state.25
Compounds 2 (X = CO) were prepared in a simple and
eﬀective manner from enantiopure, Orn-derived N-p-methoxy-
benzyl-β-lactams 1, although partial epimerization at C3
(∼20%) was observed (Chart 1).24 Recently, we have also
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reported that both the acid or basic hydrolysis of the 4-carb-
oxylic ester moiety in compounds 2 (X = CO) resulted in a fast
and complete rearrangement to β2,3,3-amino acids 3, contain-
ing a piperidin-2-one ring at position 3.26
The epimerization at C3 in the Orn-derived β-lactams,
occurring during the removal of the p-methoxybenzyl group
(Pmb) from 1,24 decreased the stereochemical outcome of the
whole 1→2→3 transformation process. To overcome the indi-
cated limitations, we decided to search for alternative methods
for the enantioselective preparation of these amino acids. We
disclose herein highly stereoselective, divergent procedures,
for the synthesis of these types of heterocycle-containing
amino acids starting from a common β-lactam intermediate.
Results and discussion
Since the loss of stereochemical integrity occurred during for-
mation of the N-unsubstituted azetidinone, because of the
strong conditions used for the N-Pmb group removal (oxi-
dation with K2S2O8), an easily detachable moiety at N1 is desir-
able. Among the described methods for the temporal
protection of β-lactam-NH, some electron-rich phenyl moieties
are within the most profusely exploited.27–29 These moieties,
exemplified by the N-p-methoxyphenyl group (Pmp), can easily
be removed by ceric ammonium nitrate (CAN) under relatively
mild conditions.30–32 In addition, this oxidative cleavage is
highly compatible with a large number of functional groups,
making this protection/deprotection procedure a good option
for our purposes.
Thus, the first step of the new synthetic sequence involved
the attachment of the Pmp group into the suitable ornithine
derivative 4 (Scheme 1). Although there are numerous reports
on N-arylation reactions, using diﬀerent palladium, copper
and nickel based catalysts, most of them require high tempera-
tures and strong bases.33,34 This could result in partial racemi-
zation in the case of amino acid derivatives. Therefore, to
avoid this issue, we have applied a described method that
requires copper(II) acetate and boronic acids, and proceeds
under mild temperature conditions and weak bases.35 Com-
pound 5 was obtained in moderate yield (47%) using these
conditions. Then, the reaction with (2S)-chloropropionic acid,
through the in situ generated acyl chloride, aﬀorded acyl
derivative 6. Upon cyclization with the phosphazene base tert-
butylimino-tri(pyrrolidino)phosphorane (BTPP), compound 6
aﬀorded the key β-lactam intermediate (3S,4S)-7 in a totally
stereoselective manner. As previously demonstrated for related
analogues, the stereochemical course of the reaction is exclu-
sively directed by the configuration of the 2-chloropropionyl
moiety.36
Contrary to that observed for N-Pmb-N-2-chloropropionyl
derivatives, no rotamers about the amide bond were found for
compound 6 (only one pattern of signals in NMR spectra). The
existing rotamer was assigned as Z by NOE experiments, since
saturation of the H2 proton enhanced the intensity of protons
at the ortho-position of the p-methoxyphenyl moiety (1.2%).
This is in agreement with previous studies on N-methyl-
acetanilides, in which the CO group and the phenyl ring are
situated on opposite sides of the amide bond.37 This seems
due to the steric hindrance between the two methyl groups
present in the N-methylacetanilides and the electron repulsion
between the CO lone pairs and the phenyl π electrons.37
As expected, removal of the p-methoxyphenyl group with
CAN yielded the N-unprotected β-lactam 8 in excellent yield
(87%), without appreciable signs of epimerization at position
3. Subsequently, to activate the β-lactam ring toward nucleo-
philic attacks, the reaction of 8 with di-tert-butyl dicarbonate
aﬀorded the corresponding N-Boc-2-oxoazetidine 9 (94%).
Finally, removal of the Z protecting group promotes the intra-
molecular opening of the β-lactam ring by the free amino
group of the side-chain, leading to the desired 2-oxoazepane
derivative 10 in high yield (90%). As expected by the stereo-
chemistry of the starting β-lactam (3S,4S),24 only the
7-exo-trig-type cyclization to the 2-oxoazepane was observed
(Scheme 2).
Scheme 1 Synthesis of the key precursor 7 from H-Orn(Z)-OMe.
Scheme 2 Synthesis of the quaternary 2-oxoazepane-containing
α,α-amino acid derivative 10.
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The synthesis of compound 10 from 2-azetidinone 7 pro-
ceeded with high eﬃcacy and total stereoselectivity. The
overall yield for the three steps was 73%, much higher than
that obtained when the corresponding N-Pmb-β-lactam was
used as the starting material (47%).24 More importantly, the
previously observed C3 epimerization was totally avoided by
application of this new procedure.
The intermolecular nucleophilic ring opening of N-Boc-
β-lactams has also been successfully applied to the synthesis
of β-amino acids, β-amino-α-hydroxy acid and β,β-disubsti-
tuted-β-amino acid derived peptides.38,39 Based on these
precedents, we envisaged a route for the preparation of confor-
mationally restricted 2-piperidinone-containing β-amino acid
derivatives, using again β-lactam 7 as the key precursor. Thus,
removal of the Z protecting group from 7 by catalytic hydrogen-
ation promoted the formation of the 3.5-spiro derivative 11 in
good yield (84%), through a 6-exo-trig ring closure (Scheme 3).
To allow the selective manipulation of the CONH group of
the β-lactam ring in an ulterior step, compound 11 was reacted
with benzyl bromide to provide the 1-benzyl derivative 12 in
almost quantitative yield. Treatment of compound 12 with
CAN led to the removal of the p-methoxyphenyl group, yielding
the N-deprotected spiro-β-lactam 13 (90%). As above, no epi-
merization at carbon 3 was observed, in contrast to what hap-
pened in the removal of the p-methoxybenzyl group from a
related spiro-lactam.26 Finally, the synthetic sequence was
completed by activation of position 1 with di-tert-butyl dicarbo-
nate and subsequent intermolecular opening of the β-lactam
ring by treatment with DBU/MeOH. The desired 2-oxopiperi-
dino-β-amino ester 14 was obtained in excellent yield from 13
in this last one-pot, two-step procedure (97%). The notable
overall yield (72%) for this 7→14 transformation was clearly
superior to that obtained in the alternative method described
by us, based on the use of the N-Pmb protecting group
(15%).26 Again, in addition to the better yield, the main attrac-
tiveness of this approach is that the 3S,4S configuration in 7 is
fully preserved along the synthetic sequence and transferred to
the (2S,3S) β-amino ester 14.
As shown in Scheme 4, compound 14 can also be prepared
in three steps from the 2-oxoazepane derivative 10, involving
N-benzylation, basic ester hydrolysis with concomitant
rearrangement,26 and re-esterification in the presence of tri-
methylsilyl diazomethane. When we compare the two routes to
14 from 7, the sequence through the spiro-β-lactam 11 was
shorter and more eﬃcient than those involving 2-oxoazepane
derivatives as key intermediates.
Conclusions
In conclusion, the rapid and eﬃcient construction of confor-
mationally constrained (3S,4S)-2-oxoazepane α,α-amino acids
and 2-piperidinone-derived (2S,3S)-β2,3,3-amino acids can be
achieved through the chemoselective manipulation of the
enantiopure Orn-derived β-lactam 7. The divergent, highly
stereocontrolled processes rely essentially on the use of the
easily removable Pmp protecting group, and on inter- and
intramolecular β-lactam ring openings. Since diﬀerent
β-lactam derivatives can readily be synthesized, either with
(3R,4R)-configuration or bearing other substituents at
C-3,24,40,41 the preparation of diverse analogues of the α,α- and
β-amino acids described here can easily be envisaged. Improve-
ments in the incorporation of the Pmp group into the starting
Orn derivative could result in higher total yield, and therefore,
in better routes towards these conformationally restricted
α- and β-amino acids.
Experimental section
General experimental details
All reagents were of commercial quality. Solvents were dried
and purified by standard methods. 1H NMR spectra were
Scheme 3 Synthesis of 2-piperidinone-derived β2,3,3–amino acid
derivative 14.
Scheme 4 Comparison of two Pmp-based routes to β2,3,3-trisubsti-
tuted amino acid derivative 14.
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recorded on a 300 MHz instrument and 13C NMR spectra were
registered at 75 MHz. Analytical TLC was performed on alu-
minium sheets with a 0.2 mm layer of silica gel F254. Silica gel
60 (230–400 mesh) was used for column chromatography.
Analytical HPLC was performed on a Eclipse Plus C18 (4.6 ×
150 mm, 5 μm) column, with a flow rate of 1.5 mL min−1,
using a tuneable UV detector set at 220 nm. Mixtures of
CH3CN (solvent A) and 0.05% TFA in H2O (solvent B) were
used in the mobile phase. Electrospray mass spectra were
recorded in the positive mode.
N-p-Methoxyphenyl-Orn(Z)-OMe (5). A mixture of p-methoxy-
phenylboronic acid (1.545 g, 10.17 mmol), and 4 Å molecular
sieves (∼0.800 g) in dry dichloromethane (120 mL), was succes-
sively treated with triethylamine (2.126 mL, 15.26 mmol), H-L-
Orn(Z)-OMe·HCl (1.612 g, 5.09 mmol) and Cu(OAc)2 (1.017 g,
5.60 mmol). The reaction was allowed to stir gently under air
at rt for 42 h and filtered over Celite. The solvent was evapo-
rated under reduced pressure and the residue was purified by
silica gel chromatography using EtOAc–hexane (1 : 3) as eluent
to give 5 (0.916 g, 47%) as a syrup. [α]20D = −18.4 (c 1.0, CHCl3).
HPLC tR = 14.51 min (gradient A/B from 5 : 95 to 80 : 20 over
20 min). 1H-NMR (300 MHz, CDCl3): δ 1.65 (m, 2H, γ-H), 1.83
(m, 2H, β-H), 3.24 (m, 2H, δ-H), 3.69 (s, 3H, OCH3), 3.73 (s, 3H,
p-OCH3, Pmp), 3.86 (bs, 1H, α-NH), 3.99 (t, 1H, J = 5.9, α-H),
4.82 (bs, 1H, δ-NH), 5.09 (s, 2H, CH2, Z), 6.59 (d, 2H, J = 8.9,
3-H and 5-H, Pmp), 6.76 (d, 2H, J = 8.9, 2-H and 6-H, Pmp),
7.35 (m, 5H, CH, Ph, Z). 13C-NMR (75 MHz, CDCl3): δ 26.5
(γ-C), 30.5 (β-C), 40.8 (δ-C), 52.3 (OCH3), 55.8 (p-OCH3, Pmp),
57.7 (α-C), 66.8 (CH2, Z), 115.1 (3-CH and 5-CH, Pmp), 115.4
(2-CH and 6-CH, Pmp), 128.2, 128.3 and 128.7 (CH, Ph, Z),
136.7 (1-C, Ph, Z), 140.9 (1-C, Pmp), 153.0 (4-C, Pmp), 156.5
(CO, Z), 174.8 (COO). (ESI) m/z = 387.0 (M + H)+, 409.0 (M +
Na)+. Elemental analysis calcd (%) for C21H26N2O5: C 65.27, H
6.78, N 7.25. Found (%): C 65.01, H 6.92, N 7.44.
N-[(S)-2-Chloropropionyl]-N-p-methoxyphenyl-L-Orn(Z)-OMe
(6). PPh3 (1.201 g, 4.58 mmol) was added to a solution of (S)-
2-chloropropionic acid (0.299 mL, 3.44 mmol) and Cl3CCN
(0.459 mL, 4.58 mmol) in THF (10 mL) at 0 °C, and the reac-
tion was stirred at rt for 30 min. Then, a solution of N-Pmp-L-
Orn(Z)-OMe (0.884 g, 2.29 mmol) and propylene oxide
(2.40 mL, 34.35 mmol) in THF (2 mL) was added dropwise to
the reaction mixture. After stirring for 48 h at rt, the solvent
was evaporated under vacuum and the residue was dissolved
in cold Et2O and filtered over Celite. The filtrate was concen-
trated under vacuum and purified by column chromatography
on silica gel using EtOAc–hexane (1 : 2) as eluent, yielding 6
(0.480 g, 44%) as a syrup. [α]20D = +24.1 (c 1.5, CHCl3). HPLC
tR = 16.54 min (gradient A/B from 5 : 95 to 80 : 20 over 20 min).
1H-NMR (300 MHz, CDCl3): δ 1.55 (d, 3H, J = 6.7, 3-H), 1.59 (m,
2H, γ-H), 1.62 (m, 1H, β-H), 1.85 (m, 1H, β-H), 3.15 (m, 2H,
δ-H), 3.74 (s, 3H, OCH3), 3.82 (s, 3H, p-OCH3, Pmp), 4.20 (q,
1H, J = 6.7, 2-H), 4.76 (t, 1H, J = 6.1, δ-NH), 4.95 (m, 1H, α-H),
5.07 (s, 2H, CH2, Z), 6.91 (d, 2H, J = 8.0, 3-H and 5-H, Pmp),
7.29 (d, 2H, J = 8.0, 2-H and 6-H, Pmp), 7.35 (s, 5H, CH, Ph, Z).
13C-NMR (75 MHz, CDCl3): δ 21.2 (3-C), 26.6 (β-C), 27.1 (γ-C),
40.7 (δ-C), 50.3 (2-C), 52.5 (OCH3), 55.6 (p-OCH3, Pmp), 60.0
(α-C), 66.8 (CH2, Z), 114.7 (3-CH and 5-CH, Pmp), 115.1 (2-CH
and 6-CH, Pmp), 128.2, 128.7 and 130.1 (CH, Ph, Z), 131.1
(1-C, Pmp), 136.7 (1-C, Ph, Z), 156.5 (CO, Z), 160.0 (4-C, Pmp),
170.7 y 171.4 (CO). (ESI) m/z = 477.0 (M + H)+. Elemental analy-
sis calcd (%) for C24H29N2O6Cl: C 60.44, H 6.13, N 5.87. Found
(%): C 60.09, H 6.21, N 6.03.
(3S,4S)-4-[3′-(Benzyloxycarbonyl)amino]propyl-4-methoxycar-
bonyl-1-p-methoxyphenyl-3-methyl-2-oxoazetidine (7). A solu-
tion of N-chloropropionyl derivative 6 (0.461 g, 0.97 mmol) in
dry CH3CN (12 mL) was treated with BTPP (0.443 mL,
1.45 mmol) under Ar atmosphere, and stirred at rt for 48 h.
After evaporation of the solvent, the residue was partitioned
between EtOAc and H2O, and the phases were separated. The
organic layer was dried over Na2SO4 and evaporated. The
residue was purified on a silica gel column using EtOAc–
hexane (2 : 3), aﬀording 7 (0.354 g, 83%) as a syrup. [α]20D =
−58.3 (c 1.4, CHCl3). HPLC tR = 15.07 min (gradient A/B from
5 : 95 to 80 : 20 over 20 min). 1H-NMR (300 MHz, CDCl3): δ 1.18
(d, 3H, J = 7.2, 3-CH3), 1.37 (m, 1H, 2′-H), 1.65 (m, 1H, 2′-H),
2.10 (dt, 1H, J = 14.4 and 4.5, 1′-H), 2.25 (dt, 1H, J = 14.4 and
4.5, 1′-H), 3.13 (m, 2H, 3′-H), 3.28 (q, 1H, J = 7.2, 3-H), 3.72
(s, 3H, OCH3), 3.73 (s, 3H, OCH3), 4.66 (bs, 1H, 3′-NH), 5.03
(s, 2H, CH2, Z), 6.79 (d, 2H, J = 9.1, 3-H and 5-H, Pmp), 7.24
(d, 2H, J = 9.1, 2-H and 6-H, Pmp), 7.29 (s, 5H, CH, Ph, Z).
13C-NMR (75 MHz, CDCl3): δ 9.9 (3-CH3), 24.2 (2′-C), 29.8
(1′-C), 40.9 (3′-C), 52.5 (3-C), 52.5 (OCH3), 55.6 (p-OCH3), 66.9
(CH2, Z), 67.7 (4-C), 114.6 (3-CH and 5-CH, Pmp), 119.5 (2-CH
and 6-CH, Pmp), 128.2, 128.3 and 128.7 (CH, Ph, Z), 130.6
(1-C, Pmp), 136.6 (1-C, Ph, Z), 156.4 and 156.6 (4-C, Pmp and
CO, Z), 166.3 (2-CO), 171.6 (COO). (ESI) m/z = 441.2 (M + H)+,
463.0 (M + Na)+. Elemental analysis calcd (%) for C24H28N2O6:
C 65.44, H 6.41, N 6.36. Found (%): C 65.19, H 6.22, N 6.28.
General procedure for the removal of the p-methoxyphenyl
group
To a solution of the corresponding p-methoxyphenyl-substi-
tuted compound (0.22 mmol) in CH3CN (2 mL) was added
slowly a solution of CAN (0.106 g, 0.19 mmol) in H2O (2 mL) at
0 °C. The addition of the CAN solution in H2O was repeated
twice, waiting 10 min between each addition. After stirring at
0 °C for another 10 min, the solvent was evaporated and the
aqueous phase was extracted with EtOAc. The combined
organic layer was washed with NaHCO3 (10%), H2O and brine,
dried over Na2SO4 and evaporated. The resulting residue was
purified on a silica gel column, using the appropriate solvent
system.
(3S,4S)-4-[3′-(Benzyloxycarbonyl)amino]propyl-4-methoxycar-
bonyl-3-methyl-2-oxoazetidine (8). Syrup (0.063 g, 87%).
Eluent: EtOAc–hexane (2 : 1). [α]20D = −32.3 (c 0.9, CHCl3). HPLC
tR = 10.65 min (gradient A/B from 5 : 95 to 80 : 20 over 20 min).
1H-NMR (300 MHz, CDCl3): δ 1.16 (d, 3H, J = 7.6, 3-CH3), 1.47
(m, 2H, 2′-H), 1.73 (m, 1H, 1′-H), 2.21 (m, 1H, 1′-H), 3.11 (q,
1H, J = 7.6, 3-H), 3.20 (m, 2H, 3′-H), 3.76 (s, 3H, OCH3), 4.87
(bs, 1H, 3′-NH), 5.09 (s, 2H, CH2, Z), 6.45 (s, 1H, 1-H), 7.35 (s,
5H, CH, Ph, Z). 13C-NMR (75 MHz, CDCl3): δ 10.8 (3-CH3), 25.8
(2′-C), 34.2 (1′-C), 40.7 (3′-C), 52.6 (OCH3), 55.6 (3-C), 64.1 (4-C),
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66.9 (CH2, Z), 128.3, 128.3 and 128.7 (CH, Ph, Z), 136.6 (1-C,
Ph, Z), 156.6 (CO, Z), 169.9 (2-CO), 172.0 (COO). (ESI) m/z =
335.0 (M + H)+, 357.0 (M + Na)+. Elemental analysis calcd (%)
for C17H22N2O5: C 61.07, H 6.63, N 8.38. Found (%): C 61.28, H
6.55, N 8.18.
(3S,4S)-6-Benzyl-1,6-diazaspiro[3.5]nonane-2,5-dione (13).
Syrup (0.051 g, 90%). Eluent: MeOH–CH2Cl2 (1 : 80). [α]
20
D =
−45.9 (c 0.4, CHCl3). HPLC tR = 12.50 min (gradient A/B from
5 : 95 to 50 : 50 over 20 min). 1H-NMR (300 MHz, CDCl3): δ 1.29
(d, 3H, J = 7.5, 3-CH3), 1.79 (m, 1H, 8-H), 1.95 (m, 1H, 8-H),
2.08 (m, 1H, 9-H), 2.15 (m, 1H, 9-H), 3.06 (q, 1H, J = 7.5, 3-H),
3.26 (m, 2H, 7-H), 4.28 (d, 1H, J = 14.5, 6-CH2), 4.96 (d, 1H, J =
14.5, 6-CH2), 6.13 (s, 1H, 1-H), 7.29 (m, 5H, CH, Bn).
13C-NMR
(75 MHz, CDCl3): δ 10.9 (3-CH3), 21.0 (8-C), 33.9 (9-C), 47.2 (7-
C), 50.7 (6-CH2), 57.7 (3-C), 60.2 (4-C), 127.8, 128.5, 128.8 and
136.9 (1-C and CH, Bn), 169.4 and 170.3 (CO). (ESI) m/z = 259.1
(M + H)+, 539.3 (2M + Na)+. Elemental analysis calcd (%) for




solution of the 1-NH oxoazetidine 8 (0.050 g, 0.15 mmol) in
dry CH2Cl2 (4 mL) was successively treated with TEA
(0.021 mL, 0.15 mmol), DMAP (0.002 g, 0.015 mmol) and di-
tert-butyldicarbonate (0.033 g, 0.15 mmol), and stirred for 3 h.
Then, the solvent was evaporated to dryness and the residue
was purified on a silica gel column using EtOAc–hexane (1 : 1)
as eluent, yielding 9 (0.061 g, 94%) as a syrup. [α]20D = −19.4
(c 1.3, CHCl3). HPLC tR = 15.59 min (gradient A/B from 5 : 95 to
80 : 20 over 20 min). 1H-NMR (300 MHz, CDCl3): δ 1.16 (d, 3H,
J = 7.5, 3-CH3), 1.49 (s, 9H, CH3, Boc), 1.55 (m, 1H, 2′-H), 1.78
(m, 1H, 2′-H), 2.14 (m, 2H, 1′-H), 3.21 (q partially overlapped,
1H, J = 7.5, 3-H), 3.23 (m, 2H, 3′-H), 3.78 (s, 3H, OCH3), 4.85 (s,
1H, 3′-NH), 5.09 (s, 2H, CH2, Z), 7.35 (s, 5H, CH, Ph, Z).
13C-NMR (75 MHz, CDCl3): δ 9.4 (3-CH3), 24.6 (2′-C), 28.1 (CH3,
Boc), 30.4 (1′-C), 41.0 (3′-C), 52.3 (3-C), 52.6 (OCH3), 66.6 (4-C),
66.9 (CH2, Z), 83.9 (C, Boc), 128.3, 128.3 and 128.7 (CH, Ph, Z),
136.6 (1-C, Ph, Z), 147.6 (CO, Boc), 156.5 (CO, Z), 166.5 (2-CO),
170.3 (COO). (ESI) m/z = 457.2 (M + Na)+. Elemental analysis
calcd (%) for C22H30N2O7: C 60.82, H 6.96, N 6.45. Found (%):
C 60.72, H 6.77, N 6.32.
(3S,4S)-4-(tert-Butoxycarbonyl)amino-4-methoxy-carbonyl-3-
methyl-2-oxoazepane (10). A solution of 9 (0.048 g,
0.11 mmol) in MeOH (10 mL) was treated with 10 wt% Pd/C
(0.011 g, 0.01 mmol). The suspension was hydrogenated at rt
and atmospheric pressure for 2 h. After filtration of the cata-
lyst, the solvent was evaporated and the crude mixture was
purified by column chromatography using EtOAc–hexane
(3 : 2) as eluent, yielding 10 (0.030 g, 90%) as a white solid. mp
183–186 °C, CH2Cl2. [α]
20
D = −40.2 (c 0.7, CHCl3). HPLC tR =
11.02 min (gradient A/B from 5 : 95 to 50 : 50 over 20 min)).
1H-NMR (300 MHz, CDCl3): δ 1.05 (d, 3H, J = 7.0, 3-CH3), 1.42
(s, 9H, CH3, Boc), 1.74 (m, 2H, 6-H), 2.19 (m, 1H, 5-H), 3.07
(m, 1H, 5-H), 3.12 (q, 1H, J = 7.0, 3-H), 3.23 (m, 1H, 7-H), 3.37
(m, 1H, 7-H), 3.74 (s, 3H, OCH3), 4.88 (s, 1H, 4-NH), 6.07 (s,
1H, 1-H). 13C-NMR (75 MHz, CDCl3): δ 13.0 (3-CH3), 25.0 (6-C),
28.4 (CH3, Boc), 36.0 (5-C), 42.2 (7-C), 43.8 (3-C), 52.5 (OCH3),
61.5 (4-C), 79.9 (C, Boc), 155.4 (CO, Boc), 172.8 (COO), 175.6 (2-
CO). (ESI) m/z = 323.3 (M + Na)+. Elemental analysis calcd (%)
for C14H24N2O5: C 55.98, H 8.05, N 9.33. Found (%): C 55.73, H
8.18, N 9.11.
(3S,4S)-1-p-Methoxyphenyl-1,6-diazaspiro[3.5]nonane-2,5-
dione (11). To a solution of N-Pmp-2-oxoazetidine 7 (0.242 g,
0.55 mmol) in MeOH (100 mL), 10 wt% Pd/C was added
(0.058 g, 0.06 mmol), and the suspension was hydrogenated at
rt and atmospheric pressure for 6 h. After filtration of the cata-
lyst, the solvent was evaporated and the crude mixture was pur-
ified by flash chromatography using MeOH–CH2Cl2 (1 : 50) as
eluent, aﬀording 11 (0.127 g, 84%) as a solid. mp 105–108 °C,
CH2Cl2. [α]
20
D = −60.9 (c 0.8, CHCl3). HPLC tR = 11.02 min (gra-
dient A/B from 5 : 95 to 50 : 50 over 20 min). 1H-NMR
(300 MHz, CDCl3): δ 1.36 (d, 3H, J = 7.4, 3-CH3), 1.88 (m, 1H,
8-H), 2.00 (m, 1H, 9-H), 2.08 (m, 1H, 8-H), 2.51 (td, 1H, J = 14.1
and 3.9, 9-H), 3.14 (q, 1H, J = 7.4, 3-H), 3.41 (m, 2H, 7-H), 3.76
(s, 3H, p-OCH3), 6.50 (bs, 1H, 6-NH), 6.84 (d, 2H, J = 9.0, 3-H
and 5-H, Pmp), 7.28 (d, 2H, J = 9.0, 2-H and 6-H, Pmp).
13C-NMR (75 MHz, CDCl3): δ 10.1 (3-CH3), 21.0 (8-C), 30.9 (9-
C), 42.6 (7-C), 55.6 (p-OCH3), 57.1 (3-C), 64.3 (4-C), 114.5 (3-CH
and 5-CH, Pmp), 120.1 (2-CH and 6-CH, Pmp), 130.0 (1-C,
Pmp), 156.5 (4-C, Pmp), 166.3 and 169.3 (CO). (ESI) m/z = 275.1
(M + H)+, 297.1 (M + Na)+. Elemental analysis calcd (%) for
C15H18N2O3: C 65.68, H 6.61, N 10.21. Found (%): C 65.60, H
6.54, N 10.32.
(3S,4S)-6-Benzyl-1-p-methoxyphenyl-1,6-diaza-spiro[3.5]-
nonane-2,5-dione (12). A solution of the spiro-β-lactam 11
(0.096 g, 0.35 mmol) in dry CH3CN (4 mL) was treated with
BTPP (0.214 mL, 0.70 mmol) and BnBr (0.084 mL, 0.70 mmol).
After microwave heating at 120 °C for 1 h, the solvent was
evaporated to dryness and the residue was dissolved in EtOAc
and washed with H2O and brine. The organic layer was dried
over Na2SO4 and evaporated to dryness. The crude mixture was
purified by chromatography on silica gel using MeOH–CH2Cl2
(1 : 80) as eluent, yielding 12 (0.125 g, 98%) as a syrup. [α]20D =
−50.0 (c 0.5, CHCl3). HPLC tR = 15.57 min (gradient A/B from
20 : 80 to 60 : 40 over 20 min). 1H-NMR (300 MHz, CDCl3):
δ 1.37 (d, 3H, J = 7.4, 3-CH3), 1.89 (m, 1H, 8-H), 2.00 (m, 1H,
9-H), 2.04 (m, 1H, 8-H), 2.51 (td, 1H, J = 13.0 and 3.9, 9-H), 3.13
(q, 1H, J = 7.4, 3-H), 3.35 (m, 2H, 7-H), 3.78 (s, 3H, p-OCH3),
4.51 (d, 1H, J = 14.3, 6-CH2), 4.84 (d, 1H, J = 14.3, 6-CH2), 6.83
(d, 2H, J = 9.1, 3-H and 5-H, Pmp), 7.24 (d, 2H, J = 9.1, 2-H and
6-H, Pmp), 7.33 (m, 5H, CH, Bn). 13C-NMR (75 MHz, CDCl3):
δ 10.4 (3-CH3), 20.7 (8-C), 31.3 (9-C), 47.3 (7-C), 50.9 (6-CH2),
55.7 (p-OCH3), 57.2 (3-C), 64.7 (4-C), 114.5 (3-CH and 5-CH,
Pmp), 120.2 (2-CH and 6-CH, Pmp), 127.9, 128.8 and 128.9
(CH, Bn), 130.2 (1-C, Pmp), 137.1 (1-C, Bn), 156.4 (4-C, Pmp),
166.4 and 167.0 (CO). (ESI) m/z = 365.1 (M + H)+, 387.1 (M +
Na)+. Elemental analysis calcd (%) for C22H24N2O3: C 72.50, H
6.64, N 7.69. Found (%): C 72.58, H 6.70, N 7.48.
Methyl (2S,3S)-3-tert-butoxycarbonylamino-2-methyl-3-
(1′-benzyl-2′-oxopiperidin-3′-yl)propionate (14). A solution of
compound 13 (0.030 g, 0.12 mmol) in dry CH2Cl2 (5 mL) was
treated with triethylamine (0.016 mL, 0.116 mmol), DMAP
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(0.002 g, 0.01 mmol) and Boc2O (0.028 g, 0.13 mmol). After
stirring at rt for 4 h, the solvent was removed under vacuum
and the residue was dissolved in MeOH (3 mL). DBU
(0.017 mL, 0.12 mmol) was added and the solution was stirred
1 h at rt. After evaporation of the solvent, the residue was puri-
fied on a silica gel column using EtOAc–hexane (1 : 3) as eluent
to yield 14 (0.044 g, 97%) as a syrup. [α]20D = +20.1 (c 1.1,
CHCl3). HPLC tR = 16.52 min (gradient A/B from 5 : 95 to
80 : 20 over 20 min). 1H-NMR (300 MHz, CDCl3): δ 1.27 (d, 3H,
J = 7.3, 2-CH3), 1.42 (s, 9H, CH3, Boc), 1.87 (m, 2H, 5′-H), 2.07
(m, 1H, 4′-H), 2.69 (m, 1H, 4′-H), 3.15 (q, 1H, J = 7.3, 2-H), 3.24
(m, 2H, 6′-H), 3.66 (s, 3H, OCH3), 4.41 (d, 1H, J = 14.7, 1′-CH2),
4.71 (d, 1H, J = 14.7, 1′-CH2), 5.53 (s, 1H, 3-NH), 7.24–7.30 (m,
5H, CH, Bn). 13C-NMR (75 MHz, CDCl3): δ 12.4 (2-CH3), 19.7
(5′-C), 28.5 (CH3, Boc), 28.8 (4′-C), 45.4 (2-C), 47.4 (6′-C), 51.3
(1′-CH2), 52.1 (OCH3), 60.0 (3-C), 79.6 (C, Boc), 127.5, 128.3,
128.7 and 137.2 (1-C and CH, Bn), 154.8 (CO, Boc), 169.8 (2′-
CO), 174.2 (1-CO). MS (ESI) m/z = 413.3 (M + Na)+, 803.5 (2M +
Na)+. Elemental analysis calcd (%) for C21H30N2O5: C 64.59, H
7.74, N 7.17. Found (%): C 64.48, H 7.65, N 7.20.
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